General Information of Drug (ID: DMEAB03)

Drug Name
1,2-dioctanoyl-sn-glycerol Drug Info
Synonyms
60514-48-9; Dicaprylglyceride; sn-1,2-Dioctanoylglycerol; (S)-3-Hydroxypropane-1,2-diyl dioctanoate; 1,2-Dicapryloyl-sn-glycerol; D-alpha,beta-Dicaprylin; BRN 1714754; CHEMBL55267; CHEBI:76979; Octanoic acid, 1-(hydroxymethyl)-1,2-ethanediyl ester, (S)-; DG(8:0/8:0/0:0); sn-1,2-dicaprilin; A-Dicaprylin; AC1L3XZK; 1,2-octanoyl-sn-diglyceride; CBiol_001868; KBioGR_000011; BSPBio_001291; KBioSS_000011; 4-02-00-00990 (Beilstein Handbook Reference); SCHEMBL466152
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
148879
ChEBI ID
CHEBI:76979
CAS Number
CAS 60514-48-9
TTD Drug ID
DMEAB03

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sodium phenylbutyrate DMXLBCQ Spinal muscular atrophy 8B61 Approved [3]
Sotrastaurin acetate DME53YS Renal transplantation NE84 Phase 2 [4]
PMID28460551-Compound-3 DMA1FRM N. A. N. A. Patented [5]
ISIS 3521 DMZFS69 N. A. N. A. Discontinued in Phase 2 [6]
BALANOL DMDLN9E N. A. N. A. Terminated [7]
RO-320432 DMFZ1YW N. A. N. A. Terminated [8]
LY-317644 DMM20PI N. A. N. A. Terminated [9]
Acteoside DM0YHKB Nephritis GB40 Terminated [10]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [11]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protein kinase C alpha (PRKCA) TTFJ8Q1 KPCA_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2435).
2 Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. J Med Chem. 2009 Jul 9;52(13):3969-81.
3 Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.
4 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
5 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
6 Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.Lung Cancer.2006 May;52(2):173-80.
7 Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
8 Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
9 Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
10 Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
11 Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
12 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.